Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:0
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [21] Update on the management of non-muscle invasive bladder cancer
    Aldousari, Saad
    Kassouf, Wassim
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2010, 4 (01): : 56 - 64
  • [22] Non-muscle invasive bladder cancer risk stratification
    Isharwal, Sumit
    Konety, Badrinath
    INDIAN JOURNAL OF UROLOGY, 2015, 31 (04) : 289 - 296
  • [23] Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer
    Soltani-Tehrani, Amir M.
    Kumar, Aman
    Pohar, Kamal S.
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 6489 - 6502
  • [24] Intravesical chemohyperthermia with mitomycin c for intermediate- & high-risk non-muscle invasive bladder cancer
    Lai, B. C. H.
    Wen, Y. -C.
    Shih, H. -J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 13 - 13
  • [25] Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer.
    Meeks, Joshua
    Carneiro, Benedito A.
    Pai, Sachin Gopalkrishn
    Oberlin, Daniel
    Rademaker, Alfred
    Fedorchak, Kyle
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [26] Role of Tissue Markers on Predicting the Prognosis of Intermediate and High-risk Non-muscle Invasive Bladder Cancer
    Abbasli, Abulfaz
    Citgez, Sinharib
    Demirdag, Cetin
    Gurbuz, Ahmet
    Erozenci, Ahmet
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2020, 19 (04): : 177 - 181
  • [27] Biomedical markers of response to intravesical BCG treatment in high-risk non-muscle invasive bladder cancer
    Jallad, S.
    Thomas, P.
    Newport, M.
    Kern, F.
    BRITISH JOURNAL OF SURGERY, 2014, 101 : 66 - 67
  • [28] Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
    Magalhaes, Joana C.
    Sousa, Maria
    Basto, Raquel
    Fraga, Teresa
    Gomes, Ines
    Fernandes, Catarina
    Mariano, Monica
    Paulo, Judy
    Madeira, Pedro
    Sousa, Gabriela
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [29] BENEFITS AND COSTS OF ALTERNATIVE GUIDELINES FOR SURVEILLANCE OF HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Su, Zhuo T.
    Mahon, Katherine
    Rezaee, Michael
    Patel, Sunil
    Townsend, Jeffrey
    Kates, Max
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1169 - E1170
  • [30] High-risk Non-muscle Invasive Bladder Cancer - "The Real Deal" for Blue Light Cystoscopy and TURBT?
    Geavlete, P.
    Geavlete, B.
    Jecu, M.
    Multescu, R.
    Georgescu, D.
    Dragutescu, M.
    BJU INTERNATIONAL, 2010, 106 (01) : 6 - 6